Cargando…

Generics versus brand-named drugs for glaucoma: the debate continues

There are three options for a given class of drugs, including brand name drugs, generic and branded generic drugs. Brand name drugs are costlier as compared to generic and branded generic drugs because they are innovator molecules developed by a company after many years of research and come into the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhartiya, Shibal, Dhingra, Deepika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Romanian Society of Ophthalmology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739547/
https://www.ncbi.nlm.nih.gov/pubmed/33367157
_version_ 1783623343952363520
author Bhartiya, Shibal
Dhingra, Deepika
author_facet Bhartiya, Shibal
Dhingra, Deepika
author_sort Bhartiya, Shibal
collection PubMed
description There are three options for a given class of drugs, including brand name drugs, generic and branded generic drugs. Brand name drugs are costlier as compared to generic and branded generic drugs because they are innovator molecules developed by a company after many years of research and come into the market with a patent, whereas branded generic drugs are produced by a different company once the patent of innovator company expires. Given that glaucoma is a chronic, largely asymptomatic disease, the choice of drugs is extremely important: the duration of medication is often lifelong, and the cost of drugs, side effects and efficacy affect compliance and adherence to therapy. This review is a brief overview of the available brand name and branded generic drugs for the management of glaucoma, in terms of efficacy and side effect profiles. It also aimed to guide rational and pragmatic drug choices in different clinical scenarios.
format Online
Article
Text
id pubmed-7739547
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Romanian Society of Ophthalmology
record_format MEDLINE/PubMed
spelling pubmed-77395472020-12-22 Generics versus brand-named drugs for glaucoma: the debate continues Bhartiya, Shibal Dhingra, Deepika Rom J Ophthalmol Reviews There are three options for a given class of drugs, including brand name drugs, generic and branded generic drugs. Brand name drugs are costlier as compared to generic and branded generic drugs because they are innovator molecules developed by a company after many years of research and come into the market with a patent, whereas branded generic drugs are produced by a different company once the patent of innovator company expires. Given that glaucoma is a chronic, largely asymptomatic disease, the choice of drugs is extremely important: the duration of medication is often lifelong, and the cost of drugs, side effects and efficacy affect compliance and adherence to therapy. This review is a brief overview of the available brand name and branded generic drugs for the management of glaucoma, in terms of efficacy and side effect profiles. It also aimed to guide rational and pragmatic drug choices in different clinical scenarios. Romanian Society of Ophthalmology 2020 /pmc/articles/PMC7739547/ /pubmed/33367157 Text en ©Romanian Society of Ophthalmology http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Bhartiya, Shibal
Dhingra, Deepika
Generics versus brand-named drugs for glaucoma: the debate continues
title Generics versus brand-named drugs for glaucoma: the debate continues
title_full Generics versus brand-named drugs for glaucoma: the debate continues
title_fullStr Generics versus brand-named drugs for glaucoma: the debate continues
title_full_unstemmed Generics versus brand-named drugs for glaucoma: the debate continues
title_short Generics versus brand-named drugs for glaucoma: the debate continues
title_sort generics versus brand-named drugs for glaucoma: the debate continues
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739547/
https://www.ncbi.nlm.nih.gov/pubmed/33367157
work_keys_str_mv AT bhartiyashibal genericsversusbrandnameddrugsforglaucomathedebatecontinues
AT dhingradeepika genericsversusbrandnameddrugsforglaucomathedebatecontinues